Who
Robert A. Lenz
Director
Company insider
Files Form 4 as: Director, NovaBridge Biosciences; Director, LB Pharmaceuticals; Head of R&D, Neumora Therapeutics.
In numbers
- Trades disclosed
- 22
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $1.1M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 14 Sep 2023
- Last trade
- 22 Aug 2026
- Last filed
- 25 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Aug 2026filed 25 Aug 2026 | NBP NovaBridge BiosciencesBiotechnology | SEC FORM 4 Code M | —17,218 | filing |
| 22 Aug 2026filed 25 Aug 2026 | NBP NovaBridge Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,486 at $0.00 | filing |
| 22 Aug 2026filed 25 Aug 2026 | NBP NovaBridge Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,486 at $0.00 | filing |
| 22 Aug 2026filed 25 Aug 2026 | NBP NovaBridge BiosciencesBiotechnology | SEC FORM 4 Code M | —17,218 | filing |
| 3 Jun 2026filed 5 Jun 2026 | LBRX LB Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | LBRX LB Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | LBRX LB Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | LBRX LB Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 18 Feb 2025filed 20 Feb 2025 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Sold | $9,3755,614 at $1.67 | filing |
| 13 Feb 2025filed 18 Feb 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —502,934 | filing |
| 13 Feb 2025filed 18 Feb 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —100,000 | filing |
| 13 Feb 2025filed 18 Feb 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —502,934 | filing |
| 13 Feb 2025filed 18 Feb 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 | filing |
| 10 Oct 2024filed 11 Oct 2024 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Sold | $125K8,260 at $15.09 | filing |
| 9 Oct 2024filed 11 Oct 2024 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Sold | $84K5,563 at $15.01 | filing |
| 18 Sep 2024filed 19 Sep 2024 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Sold | $129K10,676 at $12.09 | filing |
| 17 Sep 2024filed 19 Sep 2024 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Sold | $364K30,788 at $11.81 | filing |
| 12 Sep 2024filed 16 Sep 2024 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Sold | $377K32,948 at $11.43 | filing |
| 14 Feb 2024filed 16 Feb 2024 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 14 Feb 2024filed 16 Feb 2024 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.